BIOMARIN PHARMACEUTICAL INC (BMRN) Stock News
NASDAQ:BMRN - Nasdaq - US09061G1013 - Common Stock - Currency: USD
BMRN Latest News, Press Relases and Analysis
Top movers in Friday's after hours session
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, solid financial health, and reasonable growth prospects, making it a candidate for value investors.
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition
On May 16, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced a $270 million acquisition of Inozyme Pharma, aiming to expand its rare disease research. The all-cash deal, backed by both companies’ boards, is expected to close between July and September, giving BioMarin control of INZ-701, an enzyme replacement therapy targeting ENPP1 and ABCC6 deficiencies, life-threatening disorders caused by […]
Mentions: INZY
Morgan Stanley Analyst Maintains Buy Rating on Twilio (TWLO) Stock, Keeps $117 PT
We recently published a list of 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Twilio Inc. (NYSE:TWLO) stands against other AI stocks on Wall Street’s radar. Days after the Biden-era rule on AI chips export was rescinded, a bipartisan group of eight U.S. lawmakers […]
This Fintech Is Building an AI-Powered Bank on the Cheap -- and Trades for Less Than Book Value
LendingClub has been scooping up the technology of bankrupt AI fintech startups. LendingClub is building a modern, digital AI-powered bank, and its stock is dirt cheap. In the wake of all the economic and interest rate turmoil since the pandemic, some promising young AI fintech start-ups went bust.
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the first business development deal in 2025. Before market open on Friday, BioMarin disclosed a definitive agreement to acquire Inozyme Pharma (INZY) for $4.00/share in an all-cash transaction for a total consideration of $270M. Leerink says it had been waiting for BioMarin to do some business development as it
Mentions: INZY
Scotiabank price target raised to C$71 from C$70 at BofA
BofA raised the firm’s price target on Scotiabank (BNS) to C$71 from C$70 and keeps a Neutral rating on the shares. The cyclical rebound for the Canadian economy expected at the start of the year has been upended with a weak housing market and weak private sector job growth, the analyst tells investors in a research note. The firm, which noted that this will likely delay a peak in the credit cycle in 2H25, added that potential for policy actions from the new Carney administration combined with c
CIBC price target raised to C$100 from C$98 at BofA
BofA analyst Ebrahim Poonawala raised the firm’s price target on CIBC (CM) to C$100 from C$98 and keeps a Buy rating on the shares. The cyclical rebound for the Canadian economy expected at the start of the year has been upended with a weak housing market and weak private sector job growth, the analyst tells investors in a research note. The firm, which noted that this will likely delay a peak in the credit cycle in 2H25, added that potential for policy actions from the new Carney administration
Great News for General Motors Investors
Full-size trucks and Detroit automakers are a match made in heaven, and the former have kept a grip on the U.S. market for decades. It's a good thing too, because the margins and profits delivered with full-size trucks are gigantic compared to mainstream sedans. Sales of full-size trucks kept the lights on during dark days, but the question has been, "How feasible are trucks as electric vehicles?" Let's dig into the challenges facing trucks, and one breakthrough automaker General Motors (NYSE: GM) had recently that could substantially improve costs.
4 Best Benefits of Bank-Backed Financial Planning Tools and How You Should Use Them
Personal financial management tools can help you put yourself on the right track financially. Here are some of the best reasons to use them.
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.
Mentions: INZY
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover
Inozyme Pharma is working on an enzyme replacement therapy for ENPP1 deficiency in children.
Mentions: INZY
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announced today that BioMarin has entered into a definitive...
Mentions: INZY
BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts’ consensus estimates.
BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed better in 2025 compared to the broader market. After […]
Mentions: BLK
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from studies of VOXZOGO® (vosoritide), demonstrating meaningful impact on...
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Paul Singer’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other stock picks with huge upside potential. Paul Singer founded Elliott Investment Management in 1977 in New York. It is one of the […]
Norwegian Cruise Line Holdings Ltd. (NCLH): Among Billionaire Quants’ Two Sigma’s Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Quants’ Two Sigma’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) stands against other billionaire quants’ two sigma’s stock picks with huge upside potential. Two Sigma Advisors is one of the leading […]
1 Healthcare Stock with Competitive Advantages and 2 to Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall.
Starbucks Corporation (SBUX): A Bull Case Theory
We came across a bullish thesis on Starbucks Corporation (SBUX) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on SBUX. Starbucks Corporation (SBUX)’s share was trading at $81.66 as of May 5th. SBUX’s trailing and forward P/E were 29.69 and 28.17 respectively according to Yahoo Finance. Starbucks may appear to […]
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 20.21% and 1.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FEMY
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2025....
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential
We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among former […]
Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential
We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among former […]